Targeting Chromatin Effector Pygo2 to Enhance Immunotherapy in Prostate Cancer
Y. Zhu, Y. Zhao, J. Wen, S. Liu, T. Huang, I. Hatial, X. Peng, H. A. Janabi, G. Huang, J. Mittlesteadt, M. Cheng, A. Bhardwaj, B. Ashfeld, K. R. Kao, D. Y. Maeda, , X. Lu
This study identifies Pygo2 as a driver oncogene in prostate cancer that suppresses immune infiltration and response to immunotherapy, showing that its inhibition enhances anti-tumor immunity.
bioRxiv · Jun 16, 2022 · PreprintCancer Biology